Collegium Pharmaceutical, Inc. (COLL) Receives Average Rating of “Hold” from Brokerages
Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) have received a consensus recommendation of “Hold” from the eight ratings firms that are covering the company, Marketbeat.com reports. Two analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $21.40.
A number of analysts recently commented on COLL shares. Janney Montgomery Scott reaffirmed a “buy” rating and issued a $25.00 target price on shares of Collegium Pharmaceutical in a research report on Monday, June 12th. Needham & Company LLC reaffirmed a “buy” rating and issued a $25.00 target price on shares of Collegium Pharmaceutical in a research report on Friday, June 9th. Piper Jaffray Companies set a $14.00 target price on Collegium Pharmaceutical and gave the company a “buy” rating in a research report on Tuesday, July 25th. HC Wainwright started coverage on Collegium Pharmaceutical in a research report on Monday, September 11th. They issued a “buy” rating and a $21.00 target price for the company. Finally, Zacks Investment Research raised Collegium Pharmaceutical from a “sell” rating to a “hold” rating in a research report on Monday, August 14th.
Institutional investors and hedge funds have recently modified their holdings of the business. American International Group Inc. increased its holdings in Collegium Pharmaceutical by 27.8% during the 1st quarter. American International Group Inc. now owns 9,948 shares of the specialty pharmaceutical company’s stock worth $100,000 after purchasing an additional 2,163 shares in the last quarter. Voya Investment Management LLC bought a new stake in Collegium Pharmaceutical during the 2nd quarter worth approximately $125,000. Nationwide Fund Advisors increased its holdings in Collegium Pharmaceutical by 16.4% during the 1st quarter. Nationwide Fund Advisors now owns 10,087 shares of the specialty pharmaceutical company’s stock worth $101,000 after purchasing an additional 1,422 shares in the last quarter. Credit Suisse AG increased its holdings in Collegium Pharmaceutical by 9.4% during the 1st quarter. Credit Suisse AG now owns 13,630 shares of the specialty pharmaceutical company’s stock worth $137,000 after purchasing an additional 1,173 shares in the last quarter. Finally, UBS Group AG increased its holdings in Collegium Pharmaceutical by 283.2% during the 1st quarter. UBS Group AG now owns 13,767 shares of the specialty pharmaceutical company’s stock worth $139,000 after purchasing an additional 10,174 shares in the last quarter. 83.04% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: This piece of content was published by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.americanbankingnews.com/2017/09/20/collegium-pharmaceutical-inc-coll-receives-average-rating-of-hold-from-brokerages.html.
Collegium Pharmaceutical (NASDAQ COLL) opened at 9.69 on Wednesday. The company’s 50 day moving average price is $10.41 and its 200-day moving average price is $10.41. Collegium Pharmaceutical has a 12-month low of $9.68 and a 12-month high of $20.55. The company’s market capitalization is $286.49 million.
Collegium Pharmaceutical (NASDAQ:COLL) last issued its earnings results on Wednesday, August 9th. The specialty pharmaceutical company reported ($0.72) EPS for the quarter, beating analysts’ consensus estimates of ($0.81) by $0.09. Collegium Pharmaceutical had a negative return on equity of 93.73% and a negative net margin of 1,319.39%. The business had revenue of $3.56 million during the quarter, compared to analyst estimates of $4.07 million. Equities analysts forecast that Collegium Pharmaceutical will post ($3.00) earnings per share for the current fiscal year.
About Collegium Pharmaceutical
Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.
Receive News & Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.